All In Biotech

Drug Trial Radar · NCT01910259

MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial

A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.

Last checked: Nov 20, 2026Latest source record: Mar 26, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 445 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

445

Actual

Start

Dec 18, 2014

Primary completion

Jun 14, 2018

Study completion Jul 4, 2018

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medical Research Council; National Institute for Health Research, United Kingdom; National Multiple Sclerosis Society; University of Edinburgh; Queen Mary University of London; Keele University; University of Sheffield; University of Leeds; University of Warwick
First posted
Jul 29, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 25 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multiple sclerosis (MS) is a disabling and progressive neurological disease that affects approximately 100,000 people in the UK. Many patients with MS experience two phases of disease; early MS (also called relapsing remitting MS, RRMS) and late MS (also called secondary progressive MS (SPMS). Early MS is due to inflammation of the nerves and the insulation (called myelin) that surrounds the nerves. Early MS is often characterised by periods of "attacks" interspersed with periods of "remission" with no or low disease symptoms. Late or progressive MS, which affects the majority of patients and typically emerges after 10-15 years of disease, results from actual nerve death (also called neurodegeneration). The progressive stage of disease results not in individual attacks but slow, cumulative and irreversible disability affecting walking, balance, vision, cognition, pain control, bladder and bowel function. Critically, and unlike early disease, there is no proven treatment for the late stage of MS. This is therefore an urgent and major unmet health need. MS-SMART directly addresses this need and will evaluate in this clinical trial three drugs (fluoxetine, riluzole or amiloride), all of which have shown some promise in MS, and in particular in SPMS. The trial is randomised and blinded. Randomisation means patients can get any one of the three active drugs or the inactive placebo/dummy; blinded means that neither patients nor the doctors will know which drug or placebo patients are receiving. Randomisation and blinding are standard approaches in clinical trials to ensure unbiased testing of drugs. All patients in MS-SMART will have periodic MRI (magnetic resonance imaging) brain scans and after 96 weeks these will be analysed. We will then compare the scans of each drug to the placebo or dummy to see if any of the drugs slow the rate of brain shrinkage that normally occurs in SPMS. This measured change in brain size is the primary (major) outcome of MS-SMART.

Conditions

  • Secondary Progressive Multiple Sclerosis

Interventions

  • AmilorideDrug

    Comparison with placebo

  • RiluzoleDrug

    Comparison with placebo

  • FluoxetineDrug

    Comparison with placebo

  • PlaceboDrug

    Placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MRI-derived Percentage Brain Volume Change (PBVC).Time frame: 2 years

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Anne Rowling Regenerative Neurology Clinic, Royal Infirmary of Edinburgh

    Edinburgh, United Kingdom

  • Gartnavel Royal Hospital, 1055 Great Western Road

    Glasgow, United Kingdom

  • Brighton and Sussex University Hospitals

    Haywards Heath, United Kingdom

  • St James's University Hospital

    Leeds, United Kingdom

  • The Walton Centre

    Liverpool, United Kingdom

  • The National hospital for Neurology and Neurosurgery, University College London

    London, United Kingdom

  • The Royal Victoria Infirmary

    Newcastle, United Kingdom

  • Queens Medical Centre

    Nottingham, United Kingdom

  • John Radcliffe Hospital, Oxford University Hospitals NHS Trust

    Oxford, United Kingdom

  • Derriford Hospital

    Plymouth, United Kingdom

  • Royal Hallamshire Hospital

    Sheffield, United Kingdom

  • University Hospital of North Staffordshire

    Stoke-on-Trent, United Kingdom

  • Royal Cornwall Hospital

    Truro, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.